Research records indexed for Tirzepatide
This page carries 12 of the 2,591 records that the literature query returned for Tirzepatide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 2,579 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Tirzepatide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity pmid:39555826 | 2025 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Cardiovascular Diseases; Obesity; Stroke Volume; Body Mass Index; Follow-Up Studies. |
| Tirzepatide as Compared with Semaglutide for the Treatment of Obesity pmid:40353578 | 2025 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Body Weight; Weight Loss; Anti-Obesity Agents; Injections, Subcutaneous. |
| Tirzepatide for Obesity Treatment and Diabetes Prevention pmid:39536238 | 2025 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Gastrointestinal Diseases; Diabetes Mellitus, Type 2; Prediabetic State; Obesity; Disease Progression. |
| Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy pmid:39566869 | 2025 | Multicenter Study, Randomized Controlled Trial | human trial | Not stated | Indexed as multicenter study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Heart Ventricles; Adipose Tissue; Obesity; Magnetic Resonance Imaging, Cine; Stroke Volume. |
| Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial pmid:39551891 | 2025 | research-article, Randomized Controlled Trial | human trial | Not stated | Indexed as research-article, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Obesity; Natriuretic Peptide, Brain; Peptide Fragments; C-Reactive Protein; Stroke Volume. |
| Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight pmid:39996356 | 2025 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Absorptiometry, Photon; Body Mass Index. |
| Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes pmid:41406444 | 2025 | Clinical Trial, Phase III, Equivalence Trial | human trial | Not stated | Indexed as clinical trial, phase iii, equivalence trial. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Blood Glucose; Recombinant Fusion Proteins; Injections, Subcutaneous. |
| Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis pmid:38856224 | 2024 | Clinical Trial, Phase II, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase ii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Liver; Fatty Liver; Liver Cirrhosis; Gastric Inhibitory Polypeptide; Injections, Subcutaneous. |
| Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial pmid:38078870 | 2024 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Weight Loss; Gastric Inhibitory Polypeptide; Anti-Obesity Agents; Withholding Treatment. |
| Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity pmid:38912654 | 2024 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Sleep Apnea, Obstructive; Obesity; Body Weight; Gastric Inhibitory Polypeptide; C-Reactive Protein. |
| Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity pmid:38976257 | 2024 | Comparative Study, Research Support, Non-U.S. Gov't | other | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Retrospective Studies; Cohort Studies. |
| Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics pmid:37758044 | 2024 | Clinical Trial Protocol, Research Support, Non-U.S. Gov't | other | Not stated | Indexed as clinical trial protocol, research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents. |
Where this page sits
Compound page: Tirzepatide. Class: Incretin receptor agonists.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 166567236, tirzepatide. PubChem, National Library of Medicine (2026). pubchem:166567236
- Drugs@FDA application register query for this compound, 2 application(s) returned: NDA215866, NDA217806. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tirzepatide
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). pmid:35658024
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med (2024). pmid:38856224
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med (2025). pmid:39555826
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.